trending Market Intelligence /marketintelligence/en/news-insights/trending/kaoe7jfsu0p9zmmsqu8bvg2 content esgSubNav
In This List

Vaccinex prices IPO at $12 per share

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Vaccinex prices IPO at $12 per share

Vaccinex Inc. priced its IPO of 3,333,334 common shares at a public offering price of $12 per share.

The biotechnology company has also granted underwriters an option to buy up to an additional 500,000 common shares at the initial public offering price. The Rochester, N.Y.-based company's shares are expected to begin trading on the Nasdaq under the symbol VCNX on Aug. 9.

The offering is expected to close Aug. 13, with gross proceeds of about $40 million, Vaccinex said in an Aug. 9 release. The company will use the net proceeds from the IPO to fund the development of its therapies and repay debt, as well as for working capital and general corporate purposes.

Oppenheimer & Co. Inc. and BTIG LLC are acting as joint book-running managers of the offering. Ladenburg Thalmann & Co. Inc. is acting as co-manager.